Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Sold as Fetroja. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 1 application for Cefiderocol Sulfate Tosylate (sold as Fetroja), first approved Nov 14, 2019, with 1 new use approved and 0 published complete response letters.
First approved: Nov 14, 2019
Applications: 1
New uses approved: 1
Complete response letters: 0
Medicare spending, 2025: $11.5M
First approved in the EU: Apr 23, 2020
First approved in Japan: Nov 30, 2023
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Fetroja
Part D
$11.4M
+65%
524
Fetroja
Part B
$86K
+97%
31
Medicaid Spending
What state Medicaid programs paid pharmacies in 2025, before rebates, by product name; see every drug
Fetroja
$4.7M for 1,417 prescriptions, +11% on 2024
Adverse Event Reports (FAERS)
Cases reported to FDA naming this drug as the primary suspect, 2025 Q4 to 2026 Q3. A report does not show the drug caused the event.
Death (32), Drug resistance (20), Pneumonia (10), Septic shock (10), No adverse event (9), Off label use (9), Multiple organ dysfunction syndrome (8), Treatment failure (8), Product administered to patient of inappropriate age (7), Bacteraemia (5)
First approved in Japan 49 months after the US. PMDA's English list since 2008, matched by ingredient; see all Japanese approvals
Fetroja, new ingredientA drug with a new active ingredient indicated for the treatment of infections caused by Cefiderocol- sensitive Escherichia coli , Citrobacter spp,… · Shionogi & Co., Ltd. · Nov 30, 2023
Applications
NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA